6 Best Peptides for Muscle Preservation on GLP-1

What to Know Before Choosing a Peptide for Muscle Preservation on GLP-1

GLP-1 receptor agonists work by dramatically suppressing appetite and slowing gastric emptying. The resulting calorie deficit is large enough that the body begins pulling energy from lean tissue alongside fat stores. Clinical sub-studies of both semaglutide and tirzepatide using DEXA scanning have confirmed this: somewhere between a quarter and nearly half of total weight lost on these drugs comes from lean body mass, with the exact fraction depending on how fast someone loses, how much protein they eat, and whether they are doing any resistance training. The muscle loss is real, even if its scale is sometimes overstated in online discussions.

That problem has created a specific category of peptide use. A compound earns a slot on this list if people use it or are actively discussing using it for muscle preservation while on GLP-1 therapy. That is the whole test for inclusion. FDA approval is not required, and a thin or entirely community-based evidence record is not a reason to leave a compound off; it is a reason to describe the evidence honestly inside that compound's entry. Every regulatory tier from FDA-approved prescription compounds to research-only chemicals appears here because every tier is represented in the real-world protocols people are running.

The numbers in front of the entries are a spine for the list, not a ranking. The order reflects how prominently each compound shows up in research and documented real-world use for this specific goal, not a recommendation that one compound is better than another for you. One point worth stating plainly before the entries begin: protein intake and resistance training do more for muscle preservation on GLP-1 therapy than any peptide. Multiple clinical teams and every experienced community source agree on this. These compounds are tools people layer on top of a solid dietary and training foundation, not substitutes for one.

1. CJC-1295 with Ipamorelin: The Most Widely Used Secretagogue Stack

CJC-1295 is a synthetic analog of growth hormone releasing hormone, the signal that tells the pituitary gland to release growth hormone. Ipamorelin is a selective ghrelin receptor agonist that stimulates growth hormone release through a separate but complementary pathway. When the two are combined, they create a stronger and more sustained growth hormone pulse than either compound produces alone. That synergy is why this stack is almost always discussed and used as a pair rather than as two separate entries.

The reason this combination is so prominent for muscle preservation on GLP-1 therapy comes down to what GLP-1 drugs do to the hormonal environment. A sustained calorie deficit reduces insulin and IGF-1 signaling, the two downstream signals most responsible for keeping muscle protein synthesis running. IGF-1 is the liver's response to growth hormone, and it activates the PI3K/Akt/mTOR pathway, a cellular signaling cascade that promotes protein synthesis and suppresses the enzymes that break muscle down. The stack pushes back against the catabolic pressure a GLP-1-induced deficit creates by keeping that anabolic signal alive.

No prospective randomized controlled trial has evaluated this combination alongside GLP-1 therapy specifically against lean mass preservation endpoints as of 2026. The case for using it is built on mechanistic logic, separate human evidence for growth hormone stimulation from each compound, and substantial real-world use. Practitioners in functional and integrative medicine settings prescribe it off-label, and it consistently ranks as the most commonly used combination for this goal in community tracking.

Ipamorelin has one practical advantage over older growth hormone releasing peptides: it does not significantly raise cortisol or prolactin the way GHRP-2 or GHRP-6 do. That selectivity makes it a cleaner option, particularly for users already managing the hormonal stress of a significant calorie deficit. Both compounds are classified as research chemicals in the United States, are not FDA-approved for any human indication, and are prohibited under WADA's Class S2.

2. Tesamorelin: The FDA-Approved Option for Body Recomposition

Tesamorelin is a stabilized synthetic analog of growth hormone releasing hormone. A chemical modification to its structure extends its half-life compared to native GHRH, and it works by the same mechanism as CJC-1295: binding to GHRH receptors on the anterior pituitary and stimulating pulsatile growth hormone release, which in turn drives IGF-1 production.

What separates Tesamorelin from the rest of the compounds on this list is that it is the only one with FDA approval. Egrifta, the branded form, was approved for HIV-associated lipodystrophy, a condition where patients accumulate visceral adipose tissue as a side effect of antiretroviral therapy. Phase III randomized controlled trials supporting that approval demonstrated reductions in visceral fat of 15 to 18 percent alongside preserved or increased lean muscle cross-sectional area in participants. That body composition finding is directly relevant to anyone on a GLP-1 agent: losing visceral fat while protecting lean mass is precisely the outcome people on semaglutide or tirzepatide are trying to optimize.

The FDA approval matters for two reasons. First, the human trial data is substantially deeper than what exists for CJC-1295 or Ipamorelin. Second, it is the only compound in this class that can be obtained through a legitimate prescription pathway for its approved indication. Using it for muscle preservation during GLP-1 therapy is off-label and not an approved use, and it requires a physician and a prescription. Many functional medicine and longevity-focused clinicians prescribe it in this context, and it is often paired with Ipamorelin for a combined GHRH plus GHRP effect similar to the CJC-1295 and Ipamorelin stack, though with stronger human evidence behind the GHRH component. Tesamorelin is prohibited under WADA Class S2 regardless of prescription status.

3. MK-677: The Oral Alternative for Sustained Growth Hormone Elevation

MK-677, also known as Ibutamoren, is not technically a peptide. It is an orally active small-molecule compound that mimics the action of ghrelin at the growth hormone secretagogue receptor, the same receptor Ipamorelin targets. Activating that receptor stimulates the pituitary to release growth hormone, which elevates IGF-1 and supports an anabolic environment. The critical difference from the peptides above is delivery: MK-677 is taken by mouth.

That distinction matters in practice for people on GLP-1 therapy. Users already injecting semaglutide or tirzepatide sometimes find adding a second daily subcutaneous injection protocol to be a meaningful barrier. MK-677 removes that friction entirely. It also produces a longer-duration elevation of growth hormone and IGF-1 compared to pulsatile peptide stacks, because the oral compound has a substantially longer half-life.

The evidence picture is community-reported and derived from a research context rather than controlled human trials in GLP-1 users. MK-677 appears regularly in community protocols for this goal and ranks as the preferred option among users who are needle-averse or want to simplify an already injection-heavy protocol. There are real tradeoffs worth understanding. The ghrelin-mimetic mechanism increases appetite, which works against the core mechanism of GLP-1 therapy. Sustained non-pulsatile growth hormone elevation also carries a different long-term risk profile than the pulsatile pattern that CJC-1295 and Ipamorelin produce, and it can elevate fasting blood glucose, a meaningful concern for anyone managing metabolic health. MK-677 is not FDA-approved for any indication, is classified as a research chemical in the United States, and is prohibited under WADA Class S2.

4. Follistatin 344: Myostatin Inhibition as a Complementary Approach

Follistatin 344 approaches the muscle preservation problem from a different angle than the growth hormone secretagogues. Rather than elevating growth hormone and IGF-1, it works by binding and neutralizing myostatin, a protein the body produces specifically to limit how much muscle can grow. Myostatin is essentially a biological brake on muscle development. By inhibiting it, Follistatin 344 aims to remove that brake and allow greater muscle fiber preservation and regeneration during the catabolic pressure a GLP-1-induced deficit creates.

The biological logic here is validated by clinical evidence, though not from Follistatin 344 itself. In the BELIEVE Phase 2b trial, semaglutide was combined with bimagrumab, an antibody that blocks activin type II receptors sitting upstream of myostatin in the same pathway. That combination produced a striking result: all of the weight lost was attributed to fat mass and lean mass increased by 2.5 percent. That is the most compelling direct human evidence that targeting the myostatin and activin pathway during GLP-1 therapy can shift the fat-to-lean ratio dramatically. Follistatin 344 inhibits the same pathway through a different mechanism.

The human evidence for Follistatin 344 specifically is extremely limited. Most of what is known about myostatin inhibition via follistatin comes from animal models, where the effects on muscle mass are substantial. No clinical trial data has been published for Follistatin 344 in muscle preservation during GLP-1 therapy, or in muscle preservation more generally in humans, as of 2026. Community use exists but is less prevalent than for the growth hormone secretagogues. The compound is also a substantially larger and more complex molecule than peptides like CJC-1295, which means immunogenicity risk is higher and purity verification of research-grade material is more difficult. The pathway has direct human validation via bimagrumab; the specific compound does not yet. Follistatin 344 is not FDA-approved for any indication and is classified as a research chemical.

5. TB-500: Recovery Support to Keep Training Consistent

TB-500 is a synthetic fragment of Thymosin Beta-4, a protein that plays a central role in cell migration, wound healing, and tissue repair. Its primary mechanism involves promoting actin polymerization, the process by which cells build the internal scaffolding they need to move toward sites of damage and begin repair. It also has anti-inflammatory properties that help tissue recover from mechanical stress.

TB-500 belongs on this list for a different reason than the growth hormone compounds. It is not a direct anabolic agent in the way CJC-1295 or Tesamorelin are. It shows up consistently in community protocols for muscle preservation on GLP-1 because training hard enough to preserve muscle during a calorie deficit places significant mechanical load on tendons, ligaments, and muscle fibers, and a GLP-1-induced calorie deficit can impair the recovery capacity people rely on to sustain that training volume. Users report using TB-500 to accelerate recovery, reduce injury risk, and maintain training consistency over months of GLP-1 therapy. The path to muscle preservation here is indirect: better recovery enables more consistent resistance training, and consistent resistance training is the most powerful lever for lean mass retention during a deficit.

No human clinical trial data has been published for TB-500 specifically in muscle preservation or recovery in healthy adults as of 2026. What exists is user-reported experience from community protocols, where it appears regularly as a recovery support compound alongside GH secretagogues in GLP-1 stacks. TB-500 is not FDA-approved for any indication and is classified as a research chemical in the United States.

6. BPC-157: Connective Tissue Protection for Training Continuity

BPC-157, which stands for Body Protection Compound-157, is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. It is studied for its effects on connective tissue repair, angiogenesis, which is the growth of new blood vessels into damaged tissue, and modulation of nitric oxide signaling. The primary area of research interest has been around tendon, ligament, and joint repair.

The logic for including it in a GLP-1 muscle preservation context mirrors TB-500: it is a training continuity compound. Resistance training is the most effective intervention for preserving muscle during a calorie deficit, and anything that keeps a person training consistently supports the outcome. Users on extended GLP-1 protocols report using BPC-157 to manage joint discomfort, support connective tissue recovery between sessions, and reduce the interruptions that overuse or minor injury creates in a training program.

The human evidence for BPC-157 is limited. Most of the mechanistic work comes from animal models, primarily rodent studies, where it has shown consistent effects on soft tissue and tendon healing. Human trial data is sparse as of 2026, and the FDA has issued specific warnings regarding BPC-157 products, making it one of the more closely scrutinized research chemicals in this space. Community use for connective tissue and recovery purposes remains widespread despite those warnings. BPC-157 is not FDA-approved for any indication. Anyone considering it should be aware of the FDA's current position before proceeding.

How These Peptides Compare

Frequently Asked Questions

Do any of these compounds have FDA approval for use alongside GLP-1 therapy?

Tesamorelin is the only compound on this list with FDA approval, and that approval covers HIV-associated lipodystrophy specifically, not muscle preservation during GLP-1 therapy. Using any of these compounds alongside semaglutide or tirzepatide for muscle preservation is off-label and not an approved indication. The remaining compounds on the list are classified as research chemicals and are not FDA-approved for any human use.

Why does GLP-1 therapy cause muscle loss in the first place?

The muscle loss stems from the calorie deficit itself, not from any direct effect of GLP-1 drugs on muscle tissue. GLP-1 receptor agonists suppress appetite substantially, and the resulting deficit pushes the body to pull energy from lean tissue alongside fat. Insulin and IGF-1 signaling fall when calories are low, shifting the balance away from muscle protein synthesis and toward breakdown. Users who maintain resistance training and high protein intake consistently report far less lean tissue loss, which reinforces that the cause is the deficit rather than the drug itself.

Are these compounds safe to combine with a GLP-1 drug?

No published safety data from a controlled trial evaluates any of these peptides in combination with semaglutide or tirzepatide specifically. The safety profiles discussed in the literature apply to each compound studied independently. Clinicians who prescribe compounds like Tesamorelin or the CJC-1295 and Ipamorelin stack alongside GLP-1 therapy do so based on mechanistic reasoning and clinical experience, not on co-administration trial data. Anyone considering adding a peptide protocol to GLP-1 therapy should do so under the supervision of a physician familiar with both.

Is MK-677 actually a peptide?

MK-677 is technically a small-molecule compound rather than a peptide, meaning it is structured differently from compounds like CJC-1295 or Tesamorelin. What it shares with the peptides on this list is its mechanism: it activates the same growth hormone secretagogue receptor that ghrelin and Ipamorelin target, producing elevated growth hormone and IGF-1. It is grouped here because it serves the same functional purpose in GLP-1 protocols and because the community treats it as part of the same class of GH axis support tools.

What does the research say about combining myostatin inhibition with GLP-1 therapy?

The most direct human evidence comes from the BELIEVE Phase 2b trial, which combined semaglutide with bimagrumab, an antibody that blocks activin type II receptors sitting upstream of myostatin. That combination produced results where all of the weight lost came from fat mass and lean mass increased by 2.5 percent, a substantially better body composition outcome than GLP-1 therapy alone. Follistatin 344 targets the same pathway through a different mechanism, but no clinical trial data has been published for it specifically as of 2026. The pathway has direct human validation; the specific compound does not yet.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for muscle preservation on GLP-1 in one place.